Eva Chrenková (@evachrenkova.bsky.social)

Thrilled to share our latest study on predicting ARPI therapy failure in metastatic prostate cancer. miR-375 & LMR predict ARPI failure in CRPC. In mHSPC, platelets, CRP & CGA outperform PSA. Toward personalized therapy—guided by blood. #ProstateCancer #Oncology #Biomarkers #LiquidBiopsy

loading . . .

Platelets, Chromogranin A and C-Reactive Protein Predict Therapy Failure of Metastatic Hormone-Sensitive Prostate Cancer while miR-375 Outperforms Prostate-Specific Antigen in Stratifying Castration-R... Androgen deprivation therapy has long been the first-line treatment for hormone-sensitive prostate cancer (HSPC). After progression to castration-resistant prostate cancer (CRPC), androgen receptor pa... https://www.jmdjournal.org/article/S1525-1578(25)00063-7/abstract#ProstateCancer